Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
20
pubmed:dateCreated
2001-9-26
pubmed:abstractText
The HIV-1 gp41 envelope glycoprotein promotes fusion of the virus and cell membranes through the formation of a trimer-of-hairpins structure, in which the amino- and carboxyl-terminal regions of the gp41 ectodomain are brought together. Synthetic peptides derived from these two regions (called N and C peptides, respectively) inhibit HIV-1 entry. In contrast to C peptides, which inhibit in the nanomolar range, N peptides are weak inhibitors with IC(50) values in the micromolar range. To test the hypothesis that the weak inhibition of N peptides results from their tendency to aggregate, we have constructed chimeric variants of the N-peptide region of gp41 in which soluble trimeric coiled coils are fused to portions of the gp41 N peptide. These molecules, which present the N peptide in a trimeric coiled-coil conformation, are remarkably more potent inhibitors than the N peptides themselves and likely target the carboxyl-terminal region of the gp41 ectodomain. The best inhibitors described here inhibit HIV-1 entry at nanomolar concentrations.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-10520998, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-11229405, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-11341828, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-11395423, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-11418583, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-1438243, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-1815783, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-2279849, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-4366945, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-6049437, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-7507183, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-7538176, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-7786578, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-7937889, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-8248779, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-8312047, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-8371754, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-8846219, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9108481, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9163431, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9356444, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9439994, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9444991, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9630213, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9689046, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9809555, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9811701, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9837709, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9861018, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9876926, http://linkedlifedata.com/resource/pubmed/commentcorrection/11572974-9888845
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:day
25
pubmed:volume
98
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
11187-92
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:11572974-Amino Acid Sequence, pubmed-meshheading:11572974-Anti-HIV Agents, pubmed-meshheading:11572974-Cell Line, pubmed-meshheading:11572974-Cell Membrane, pubmed-meshheading:11572974-Circular Dichroism, pubmed-meshheading:11572974-Drug Design, pubmed-meshheading:11572974-Frameshift Mutation, pubmed-meshheading:11572974-Genes, env, pubmed-meshheading:11572974-HIV Envelope Protein gp41, pubmed-meshheading:11572974-HIV-1, pubmed-meshheading:11572974-Humans, pubmed-meshheading:11572974-Luciferases, pubmed-meshheading:11572974-Models, Molecular, pubmed-meshheading:11572974-Molecular Sequence Data, pubmed-meshheading:11572974-Peptides, pubmed-meshheading:11572974-Protein Structure, Secondary, pubmed-meshheading:11572974-Recombinant Fusion Proteins, pubmed-meshheading:11572974-Transfection
pubmed:year
2001
pubmed:articleTitle
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
pubmed:affiliation
Howard Hughes Medical Institute, Whitehead Institute for Biomedical Research, Department of Biology, Massachusetts Institute of Technology, Nine Cambridge Center, Cambridge, MA 02142, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.